Description: Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.
Home Page: www.oncolyticsbiotech.com
ONC Technical Analysis
322 11th Avenue SW
Calgary,
AB
T2R 0C5
Canada
Phone:
403 670 7377
Officers
| Name | Title |
|---|---|
| Dr. Matthew C. Coffey M.B.A., Ph.D. | Pres, CEO & Director |
| Mr. Kirk J. Look C.A., CA | Chief Financial Officer |
| Mr. Andrew R. de Guttadauro | Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc |
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer |
| Ms. Allison Hagerman P.Eng., P.M.P. | VP of Product Devel. |
| Jon Patton | Director of Investor Relations & Communication |
| Dr. Grey Wilkinson Ph.D. | Scientist of Translational Medicine |
| Mr. John Mark Lievonen F.C.A., FCA | Consultant |
| Dr. Daniel Douglas Von Hoff F.A.C.P., FACP, M.D. | Consultant |
Exchange: TO
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.8226 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 26 |